After 16 years writing about biotech stocks for TheStreet, it's time for this writer to say goodbye and thank you.
Hope springs eternal, until it's dashed on the rocks and buried at sea.
Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.
100% response rate with zero relapses are the latest update from Bluebird's BB2121 study in multiple myeloma patients.
This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.
Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.
Incyte and Merck are combining two cancer immunotherapy drugs to treat patients with non-small cell lung cancer.
The Loxo data also represent another advance for precision cancer medicine, in which patients are treated with drugs that target specific tumor mutations, regardless of where the cancer originates.
A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
An FDA advisory panel is reviewing Puma's breast cancer drug neratinib.
The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.
Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.
LJPC-501 reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.
The new Merck survival data were included in a research abstract for next month's American Society of Clinical Oncology (ASCO) annual meeting that was distributed on Wednesday night.
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
Monday's licensing deal is a nice win for Akebia because Fresenius is the largest dialysis provider in North America, serving approximately 40% of dialysis patients in the U.S.
The clinical trial shutdown ordered by regulators in its own country casts another shadow of doubt over AB Science at a most inopportune time.
XBiotech offered no reason for Thornburg's resignation, but he left two weeks after European regulators issued a preliminary recommendation to reject the application for the company's colon cancer drug Xilonix.
Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.
Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?
A presentation on May 18 will shed more light on the efficacy and safety of AB Science's ALS drug masitinib.
The death rattled Kite investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics.